Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22762684 | 0.81 | OXTR (0.37) | ALDH1A1MAPTGLATSHRMLYCD | |
| SCHEMBL23517270 | 0.81 | APP (0.39) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL26051896 | 0.77 | KDM4E (0.33) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL21901905 | 0.73 | KDM4E (0.31) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL22688401 | 0.73 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL21785057 | 0.73 | OPRM1 (0.49) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL5045338 | 0.71 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL5045325 | 0.69 | ALDH1A1 (0.46) | ALDH1A1KDM4EGAAMAPTTHRB | |
| SCHEMBL22665374 | 0.69 | ALDH1A1 (0.50) | ALDH1A1MAPTHTTSMN1; SMN2GLA | |
| SCHEMBL29173245 | 0.69 | BCL2A1 (0.60) | ALDH1A1KDM4EGAAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | ALDH1A1 477/4885KDM4E 4764/4885GAA 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.